We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effects of Aquamin F on Osteoarthritis of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00452101
Recruitment Status : Completed
First Posted : March 26, 2007
Last Update Posted : March 26, 2007
Information provided by:
Marigot Ltd.

Brief Summary:

The objective of this trial is to evaluate the effect of Aquamin F alone or in combination with glucosamine sulfate versus placebo on symptoms of joint pain, stiffness and immobility in subjects with painful osteoarthritis of the knee. The following hypotheses were tested:

(Hypothesis 1) After 12 weeks of treatment, subjects taking Aquamin F alone or in combination with glucosamine sulfate will have significantly less joint pain, stiffness and immobility compared to subjects taking glucosamine sulfate alone or placebo alone.

(Hypothesis 2) No significant differences will be seen for adverse events between the subjects taking Aquamin F, glucosamine sulfate, Aquamin F + glucosamine sulfate or placebo.

Condition or disease Intervention/treatment Phase
Osteoarthritis of the Knee Drug: Aquamin F Phase 1 Phase 2

Detailed Description:
Method: Subjects were randomized to receive 12 weeks of Glucosamine sulfate vs Aquamin F vs Placebo vs Aquamin F + Glucosamine sulfate while controlling for pain with acetaminophen. Subjects were then followed for blood chemistry measurements only over an additional 12-week period specifically to assess blood calcium levels post treatment. All participants were subjected to the same diet and exercise regimen and measurements included: WOMAC scores (pain, stiffness, mobility, total score), 6 Minute Walking Distances, active and passive range of motion measurements, DXA scans, blood chemistry, hematology, CRP levels and lipid profiles as well as rescue medication diary measurements and adverse event assessments. An independent statistician analyzed the data using independent t-tests and ANCOVA for between-group comparisons and matched-pair t-tests for within-group comparisons of patients included in ITT-LOCF and completer analyses.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Randomized, Placebo Controlled Trial: Effects of Aquamin F Alone or in Combination With Glucosamine Sulfate on Joint Mobility and Pain in Osteoarthritis of the Knee
Study Start Date : January 2006
Actual Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Primary Outcome Measures :
  1. WOMAC scores (pain, stiffness, mobility, total score)
  2. 6 Minute Walking Distances
  3. Active and passive range of motion (goniometer measurements)

Secondary Outcome Measures :
  1. DXA scans for bone mineral density
  2. CRP levels
  3. Lipid profiles
  4. Rescue medication diary measurements
  5. The safety/toxicology measurements included a Chemistry Profile (including serum calcium)
  6. Complete Blood Counts
  7. Adverse Events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • Subjects aged 35 to 75, male or female
  • Subjects diagnosed with symptomatic moderate to severe osteoarthritis of the knee according to the modified criteria of the American College of Rheumatology17, 18
  • Subjects who present with osteoarthritis of the knee as judged by symptoms and disabilities detectable through published, validated questionnaires or previous diagnosis by a physician.
  • Subjects who are symptomatic with daily or near daily pain and stiffness from osteoarthritis.
  • Subjects with screening WOMAC Osteoarthritis Index total score (transformed score) of not more than 75.
  • Subjects with ability to comprehend and complete the questionnaires and forms.
  • Subjects whose schedules permit clinic evaluations every four weeks.
  • Subjects who are willing to stop taking calcium supplements, if any, and to restrict consumption of high calcium foods to 600 mg (two dairy serving) per day
  • Subjects with a high probability of compliance with study procedures and test article consumption.
  • Subjects willing and able to follow protocol guidelines and schedules, and complete diaries.
  • Subjects who are likely to abstain from taking unauthorized supplements or participating in any other clinical trial or experimental treatment during this trial
  • Subjects with normal gastrointestinal digestion and absorption.

Exclusion Criteria

  • Subjects suffering from inflammatory arthritis, gout, pseudogout, Paget's disease, seizure disorder, insulin dependent diabetes mellitus, uncontrolled hypertension, unstable cardiovascular disease, active hepatic or renal disease, active cancer and/or HIV infection.
  • Subjects who are non-ambulatory or bedridden due to osteoarthritis.
  • Subjects who are dependent on prescription drugs to control pain.
  • Subjects on any other clinical trial or experimental treatment in the past 3 months
  • Subjects who are pregnant, lactating, or at risk of becoming pregnant.
  • Subjects who have received:

    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) within 48 hours prior to study enrollment.
    • Intramuscular or systemic corticosteroid injection within 4 weeks prior to study enrollment.
    • Intra-articular corticosteroid injection within 2 months prior to study enrollment.
    • Intra-articular hyaluronic acid injection within 4 months prior to study enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00452101

Sponsors and Collaborators
Marigot Ltd.
Layout table for investigator information
Study Chair: John L Zenk, MD
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00452101    
Other Study ID Numbers: MARC005-065
First Posted: March 26, 2007    Key Record Dates
Last Update Posted: March 26, 2007
Last Verified: March 2007
Keywords provided by Marigot Ltd.:
Clinical trial
Aquamin F
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases